Trump Administration Bars U.S. Travelers From Congo Flights Amid Ebola Outbreak 
GLP-1 Weight-Loss Drug Use Surges Among U.S. Children 
Venezuela Earthquake Health Risks Rise as Disease Monitoring Intensifies 
Jeff Bezos Invests $32 Billion in Blue Origin as Space Firm Targets Major Growth 
SK Biopharmaceuticals Secures Global Rights to Biohaven Epilepsy Drug Opakalim 
Trump Signs Order to Cut Routine Childhood Vaccines 
France Battles Mediterranean Wildfires as Heatwave Fuels Fire Risk 
US-Backed Pediatric HIV Treatment Drops After Foreign Aid Changes, Study Finds 
SoftBank Raises $11.1 Billion in Bond Sale to Fund OpenAI Investment 
Novo Nordisk Strikes €1.17 Billion Nanexa Drug Delivery Deal 
Dubai’s connectivity remains strong in an uncertain world 
EQT Plans €1.7 Billion Sale of Parques Reunidos Stake 
SpaceXAI to Double Nvidia Chips at Colossus 2 by Year-End 
BMW 2028 Margin Target Could Fall Below Consensus, UBS Says 
US 10-Year Treasury Yield at 6% Emerges as New Market Risk Threshold 
Airbus Finds A321neo Fuselage Quality Issue 
Add as a preferred source on Google
Novo Nordisk shares plunged more than 10% in mid-morning trading in Copenhagen on Monday after the pharmaceutical giant announced that its experimental obesity drug, CagriSema, failed to meet a primary endpoint in a closely watched clinical trial. The update intensifies competition in the rapidly expanding weight loss drug market, where Novo Nordisk faces mounting pressure from rival Eli Lilly.
The 84-week open-label head-to-head study was designed to demonstrate that CagriSema was non-inferior to Eli Lilly’s blockbuster obesity treatment, Tirzepatide, in reducing body weight. According to Novo Nordisk, patients treated with CagriSema achieved an average weight loss of 23%, while those receiving Tirzepatide recorded a superior 25.5% reduction. As a result, the trial did not meet its primary objective of proving that CagriSema was not lagging behind Tirzepatide in weight loss efficacy.
The disappointing trial results sent Novo Nordisk stock sharply lower, adding to a challenging year for the Danish drugmaker. In 2025, Novo shares have fallen by 49%, reflecting investor concerns over intensifying competition and shifting dynamics in the obesity treatment sector. The company previously secured a dominant position with its blockbuster drugs Wegovy and Ozempic, both of which fueled significant growth amid surging global demand for weight management medications.
However, competition has grown fiercer, particularly from Eli Lilly, whose Tirzepatide has gained significant traction. Additionally, telehealth providers offering lower-cost compounded alternatives have further pressured pricing and market share.
Despite the setback, Novo Nordisk confirmed that CagriSema was submitted to the U.S. Food and Drug Administration (FDA) for approval in December, with a regulatory decision expected by late 2026. The company recently announced board-level changes, including the appointment of industry veterans and Lars Rebien Sorensen as chairman, signaling a strategic push to strengthen leadership and respond more aggressively to U.S. market challenges.
Investors will now closely monitor regulatory developments and Novo Nordisk’s strategy to defend its position in the booming obesity drug market.
